These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 38243752

  • 1. Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
    Becker CM, Johnson NP, As-Sanie S, Arjona Ferreira JC, Abrao MS, Wilk K, Imm SJ, Mathur V, Perry JS, Wagman RB, Giudice LC.
    Hum Reprod; 2024 Mar 01; 39(3):526-537. PubMed ID: 38243752
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
    Giudice LC, As-Sanie S, Arjona Ferreira JC, Becker CM, Abrao MS, Lessey BA, Brown E, Dynowski K, Wilk K, Li Y, Mathur V, Warsi QA, Wagman RB, Johnson NP.
    Lancet; 2022 Jun 18; 399(10343):2267-2279. PubMed ID: 35717987
    [Abstract] [Full Text] [Related]

  • 4. Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain.
    As-Sanie S, Abrao MS, Reznichenko G, Wilk K, Zhong Y, Perry J, Hunsche E, Soulban G, Becker CM.
    Fertil Steril; 2024 Oct 18; 122(4):687-695. PubMed ID: 38906210
    [Abstract] [Full Text] [Related]

  • 5. Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain.
    Blair HA.
    Drugs; 2024 Apr 18; 84(4):449-457. PubMed ID: 38592603
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study.
    D'Hooghe T, Fukaya T, Osuga Y, Besuyen R, López B, Holtkamp GM, Miyazaki K, Skillern L.
    Hum Reprod; 2019 May 01; 34(5):813-823. PubMed ID: 31067329
    [Abstract] [Full Text] [Related]

  • 7. A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.
    Diamond MP, Stewart EA, Williams ARW, Carr BR, Myers ER, Feldman RA, Elger W, Mattia-Goldberg C, Schwefel BM, Chwalisz K.
    Hum Reprod Open; 2019 May 01; 2019(4):hoz027. PubMed ID: 31777761
    [Abstract] [Full Text] [Related]

  • 8. Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results.
    Osuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N.
    BMC Womens Health; 2021 Jun 21; 21(1):250. PubMed ID: 34154590
    [Abstract] [Full Text] [Related]

  • 9. ESHRE guideline: endometriosis.
    Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, King K, Kvaskoff M, Nap A, Petersen K, Saridogan E, Tomassetti C, van Hanegem N, Vulliemoz N, Vermeulen N, ESHRE Endometriosis Guideline Group .
    Hum Reprod Open; 2022 Jun 21; 2022(2):hoac009. PubMed ID: 35350465
    [Abstract] [Full Text] [Related]

  • 10. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
    Stewart EA, Al-Hendy A, Lukes AS, Madueke-Laveaux OS, Zhu E, Proehl S, Schulmann T, Marsh EE.
    Am J Obstet Gynecol; 2024 Feb 21; 230(2):237.e1-237.e11. PubMed ID: 37863160
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
    Stewart EA, Diamond MP, Williams ARW, Carr BR, Myers ER, Feldman RA, Elger W, Mattia-Goldberg C, Schwefel BM, Chwalisz K.
    Hum Reprod; 2019 Apr 01; 34(4):623-634. PubMed ID: 30865281
    [Abstract] [Full Text] [Related]

  • 12. Top 10 priorities for future infertility research: an international consensus development study†  ‡.
    Duffy JMN, Adamson GD, Benson E, Bhattacharya S, Bhattacharya S, Bofill M, Brian K, Collura B, Curtis C, Evers JLH, Farquharson RG, Fincham A, Franik S, Giudice LC, Glanville E, Hickey M, Horne AW, Hull ML, Johnson NP, Jordan V, Khalaf Y, Knijnenburg JML, Legro RS, Lensen S, MacKenzie J, Mavrelos D, Mol BW, Morbeck DE, Nagels H, Ng EHY, Niederberger C, Otter AS, Puscasiu L, Rautakallio-Hokkanen S, Sadler L, Sarris I, Showell M, Stewart J, Strandell A, Strawbridge C, Vail A, van Wely M, Vercoe M, Vuong NL, Wang AY, Wang R, Wilkinson J, Wong K, Wong TY, Farquhar CM, Priority Setting Partnership for Infertility, AlAhwany H, Balaban O, Barton F, Beebeejaun Y, Boivin J, Bosteels JJA, Calhaz-Jorge C, D’Angelo A, F. Dann L, J. De Jonge C, du Mez E, A. Ferriani R, Gerval MO, J. Gingel L, Greenblatt EM, Hartshorne G, Helliwell C, Hughes LJ, Jo J, Jovanović J, Kiesel L, Kietpeerakool C, Kostova E, Kucuk T, Kumar R, Lawrence RL, Lee N, Lindemann KE, Loto OM, Lutjen PJ, MacKinven M, Mascarenhas M, McLaughlin H, Mourad SM, Nguyen LK, Norman RJ, Olic M, Overfield KL, Parker-Harris M, Repping S, Rizzo R, Salacone P, Saunders CH, Sengupta R, Sfontouris IA, Silverman NR, Torrance HL, Uphoff EP, Wakeman SA, Wischmann T, Woodward BJ, Youssef MA.
    Hum Reprod; 2020 Dec 01; 35(12):2715-2724. PubMed ID: 33252677
    [Abstract] [Full Text] [Related]

  • 13. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.
    Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer DF, Diamond MP, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Singh SS, Rechberger T, Agarwal SK, Duan WR, Schwefel B, Thomas JW, Peloso PM, Ng J, Soliman AM, Chwalisz K.
    Obstet Gynecol; 2018 Jul 01; 132(1):147-160. PubMed ID: 29889764
    [Abstract] [Full Text] [Related]

  • 14. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas.
    Al-Hendy A, Lukes AS, Poindexter AN, Venturella R, Villarroel C, McKain L, Li Y, Wagman RB, Stewart EA.
    Obstet Gynecol; 2022 Dec 01; 140(6):920-930. PubMed ID: 36357960
    [Abstract] [Full Text] [Related]

  • 15. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.
    Al-Hendy A, Venturella R, Arjona Ferreira JC, Li Y, Soulban G, Wagman RB, Lukes AS.
    Am J Obstet Gynecol; 2023 Dec 01; 229(6):662.e1-662.e25. PubMed ID: 37666383
    [Abstract] [Full Text] [Related]

  • 16. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials.
    Stewart EA, Lukes AS, Venturella R, Arjona Ferreira JC, Li Y, Hunsche E, Wagman RB, Al-Hendy A.
    Obstet Gynecol; 2022 Jun 01; 139(6):1070-1081. PubMed ID: 35675604
    [Abstract] [Full Text] [Related]

  • 17. Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis.
    Pokrzywinski RM, Soliman AM, Snabes MC, Chen J, Taylor HS, Coyne KS.
    Fertil Steril; 2021 Feb 01; 115(2):423-430. PubMed ID: 33066973
    [Abstract] [Full Text] [Related]

  • 18. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
    J Urol; 2023 Jul 01; 210(1):224-226. PubMed ID: 37119051
    [Abstract] [Full Text] [Related]

  • 19. A Plain Language Summary to learn about relugolix combination therapy for the treatment of pain associated with endometriosis.
    Giudice LC, As-Sanie S, Arjona Ferreira JC, Becker CM, Abrao MS, Lessey BA, Dynowski K, Wilk K, Li Y, Mathur V, Wagman RB, Johnson NP.
    Pain Manag; 2023 Nov 01; 13(11):631-640. PubMed ID: 37982388
    [Abstract] [Full Text] [Related]

  • 20. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.
    Osuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N.
    Fertil Steril; 2021 Feb 01; 115(2):397-405. PubMed ID: 32912633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.